Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson's disease etiology

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Coetzee, Simon G ^a   Pierce, Steven ^b   Brundin, Patrik ^b   Brundin, Lena ^b   Hazelett, Dennis J ^a   Coetzee, Gerhard A ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR;

GENE EXPRESSION REGULATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN CHROMOSOME; METABOLISM; PARKINSON DISEASE; PROMOTER REGION; QUANTITATIVE TRAIT LOCUS; REGULATORY SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

CHROMOSOMES, HUMAN; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LINKAGE DISEQUILIBRIUM; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; QUANTITATIVE TRAIT LOCI; REGULATORY SEQUENCES, NUCLEIC ACID; TRANSCRIPTION FACTORS;

EID: 84979743272     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30509     Document Type: Article

References (63)

1. Berg, D. et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord 29, 454-462 (2014).
2. Braak, H. et al. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 21, 2042-2051 (2006).
3. Bras, J., Guerreiro, R., Hardy, J. SnapShot: Genetics of Parkinson's disease. Cell 160, 570-570 e571 (2015).
4. Kalinderi, K., Bostantjopoulou, S., Fidani, L. The genetic background of Parkinson's disease: current progress and future prospects. Acta Neurol Scand (2016).
5. Langston, J. W., Schule, B., Rees, L., Nichols, R. J., Barlow, C. Multisystem Lewy body disease and the other parkinsonian disorders. Nat Genet 47, 1378-1384 (2015).
6. Gasser, T. Usefulness of Genetic Testing in PD and PD Trials: A Balanced Review. J Parkinsons Dis 5, 209-215 (2015).
7. Nalls, M. A. et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46, 989-993 (2014).
8. Verstraeten, A., Theuns, J., Van Broeckhoven, C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet 31, 140-149 (2015).
9. Yao, L., Shen, H., Laird, P. W., Farnham, P. J., Berman, B. P. Inferring regulatory element landscapes and transcription factor networks from cancer methylomes. Genome Biol 16, 105 (2015).
10. Coetzee, S. G., Coetzee, G. A., Hazelett, D. J. motifbreakR: an R/Bioconductor package for predicting variant effects at transcription factor binding sites. Bioinformatics 31, 3847-3849 (2015).
11. Coetzee, S. G., Rhie, S. K., Berman, B. P., Coetzee, G. A., Noushmehr, H. FunciSNP: an R/bioconductor tool integrating functional non-coding data sets with genetic association studies to identify candidate regulatory SNPs. Nucleic Acids Res 40, e139 (2012).
12. Farh, K. K. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337-343 (2015).
13. Hnisz, D. et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol Cell 58, 362-370 (2015).
14. Parker, S. C. et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc Natl Acad Sci USA 110, 17921-17926 (2013).
15. Denuc, A., Marfany, G. SUMO and ubiquitin paths converge. Biochem Soc Trans 38, 34-39 (2010).
16. Ledo, N. et al. Functional genomic annotation of genetic risk loci highlights inflammation and epithelial biology networks in CKD. J Am Soc Nephrol 26, 692-714 (2015).
17. Urquhart, J. E. et al. DMRTA2 (DMRT5) is mutated in a novel cortical brain malformation. Clin Genet (2016).
18. Anney, R. et al. A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet 19, 4072-4082 (2010).
19. Mariani, J. et al. FOXG1-Dependent Dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum Disorders. Cell 162, 375-390 (2015).
20. Kim, K. H., Rosen, A., Bruneau, B. G., Hui, C. C., Backx, P. H. Iroquois homeodomain transcription factors in heart development and function. Circulation research 110, 1513-1524 (2012).
21. Steger, M. et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. eLife 5 (2016).
22. Chen, C. et al. Correlation between DNA methylation and gene expression in the brains of patients with bipolar disorder and schizophrenia. Bipolar Disord 16, 790-799 (2014).
23. Koga, S. et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 85, 404-412 (2015).
24. Hirsch, E. C., Jenner, P., Przedborski, S. Pathogenesis of Parkinson's disease. Mov Disord 28, 24-30 (2013).
25. Ilieva, H., Polymenidou, M., Cleveland, D. W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 187, 761-772 (2009).
26. Halliday, G. M., Holton, J. L., Revesz, T., Dickson, D. W. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 122, 187-204 (2011).
27. Braak, H., de Vos, R. A., Bohl, J., Del Tredici, K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 396, 67-72 (2006).
28. Mahlknecht, P., Seppi, K., Poewe, W. The Concept of Prodromal Parkinson's Disease. J Parkinsons Dis 5, 681-697 (2015).
29. Berg, D. et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord 30, 1600-1611 (2015).
30. Hirsch, E. C., Hunot, S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8, 382-397 (2009).
31. Hirsch, E. C., Vyas, S., Hunot, S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord 18 Suppl 1, S210-S212 (2012).
32. Collins, L. M., Toulouse, A., Connor, T. J., Nolan, Y. M. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 62, 2154-2168 (2012).
33. Gao, H. M. et al. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28, 7687-7698 (2008).
34. Angot, E., Steiner, J. A., Hansen, C., Li, J. Y., Brundin, P. Are synucleinopathies prion-like disorders? Lancet Neurol 9, 1128-1138 (2010).
35. Lebouvier, T. et al. The second brain and Parkinson's disease. Eur J Neurosci 30, 735-741 (2009).
36. Svensson, E. et al. Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol 78, 522-529 (2015).
37. Nalls, M. A. et al. Genetic comorbidities in Parkinson's disease. Hum Mol Genet 23, 831-841 (2014).
38. Hakimi, M. et al. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm (Vienna) 118, 795-808 (2011).
39. Puccini, J. M. et al. Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders. J Neurosci 35, 5271-5283 (2015).
40. Moehle, M. S. et al. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32, 1602-1611 (2012).
41. Allen Reish, H. E., Standaert, D. G. Role of alpha-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis 5, 1-19 (2015).
42. Bae, E. J. et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32, 13454-13469 (2012).
43. George, S., Brundin, P. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation. J Parkinsons Dis 5, 413-424 (2015).
44. Rezai-Zadeh, K., Gate, D., Szekely, C. A., Town, T. Can peripheral leukocytes be used as Alzheimer's disease biomarkers? Expert Rev Neurother 9, 1623-1633 (2009).
45. Mutnal, M. B., Hu, S., Schachtele, S. J., Lokensgard, J. R. Infiltrating regulatory B cells control neuroinflammation following viral brain infection. J Immunol 193, 6070-6080 (2014).
46. Kedmi, M., Bar-Shira, A., Gurevich, T., Giladi, N., Orr-Urtreger, A. Decreased expression of B cell related genes in leukocytes of women with Parkinson's disease. Mol Neurodegener 6, 66 (2011).
47. Kobo, H. et al. Down-regulation of B cell-related genes in peripheral blood leukocytes of Parkinson's disease patients with and without GBA mutations. Mol Genet Metab 117, 179-185 (2016).
48. Stevens, C. H. et al. Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol 252, 95-99 (2012).
49. Wang, L. et al. Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. Exp Neurol 251, 22-29 (2014).
50. Wang, L., Li, C., Zhang, Y., Qiao, C., Ye, Y. Synthesis and biological evaluation of benzofuroxan derivatives as fungicides against phytopathogenic fungi. J Agric Food Chem 61, 8632-8640 (2013).
51. Santiago, J. A., Potashkin, J. A. Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol Med 19, 176-186 (2013).
52. Gao, X., O'Reilly, E. J., Schwarzschild, M. A., Ascherio, A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology 86, 520-526 (2016).
53. Heymann, F., Tacke, F. Immunology in the liver-from homeostasis to disease. Nat Rev Gastroenterol Hepatol 13, 88-110 (2016).
54. Kordower, J. H. et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136, 2419-2431 (2013).
55. Pakkenberg, B. et al. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54, 30-33 (1991).
56. Iacono, D. et al. Parkinson disease and incidental Lewy body disease: Just a question of time? Neurology 85, 1670-1679 (2015).
57. Ross, R. A., Judd, A. B., Pickel, V. M., Joh, T. H., Reis, D. J. Strain-dependent variations in number of midbrain dopaminergic neurones. Nature 264, 654-656 (1976).
58. Tada, S. et al. Characterization of mesendoderm: a diverging point of the definitive endoderm and mesoderm in embryonic stem cell differentiation culture. Development 132, 4363-4374 (2005).
59. Hynes, M., Poulsen, K., Tessier-Lavigne, M., Rosenthal, A. Control of neuronal diversity by the floor plate: contact-mediated induction of midbrain dopaminergic neurons. Cell 80, 95-101 (1995).
60. Placzek, M., Yamada, T., Tessier-Lavigne, M., Jessell, T., Dodd, J. Control of dorsoventral pattern in vertebrate neural development: induction and polarizing properties of the floor plate. Development Suppl 2, 105-122 (1991).
61. Wang, M. Z. et al. Induction of dopaminergic neuron phenotype in the midbrain by Sonic hedgehog protein. Nat Med 1, 1184-1188 (1995).
62. Freedman, M. L. et al. Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet 43, 513-518 (2011).
63. Roadmap Epigenomics, C. et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317-330 (2015).